Genomics is becoming the future of medicine as technological advancements continue to unlock our DNA’s vast potential. Given ...

Key Insights Significant control over BioNTech by private equity firms implies that the general public has more ...

BioNTech SE (NASDAQ:BNTX – Get Free Report) was the target of some unusual options trading on Tuesday. Stock traders acquired 4,599 call options on the company. This represents an increase of ...

The BioNTech SE ADR BNTX slipped 3.73% to $122.15 Wednesday, on what proved to be an all-around favorable trading session for ...

Morgan Stanley analyst Terence Flynn maintained a Buy rating on BioNTech SE (BNTX – Research Report) today and set a price target of $145.00.

BioNTech (BNTX) stock slipped after signing $1B deals with NIH and the University of Pennsylvania to resolve COVID vaccine ...

The BioNTech SE ADR BNTX rose 5.55% to $126.88 Tuesday, on what proved to be an all-around dismal trading session for the ...

Geode Capital Management LLC trimmed its stake in BioNTech SE (NASDAQ:BNTX – Free Report) by 0.8% during the 3rd quarter, ...

Jefferies sees Arbutus (ABUS) potentially benefitting from vaccines being developed by Moderna (MRNA) and Pfizer (PFE)/GSK ...

Investors speculated on Covid vaccine firms. Despite the seasonal strength for flu-related vaccines ending, Moderna (MRNA) ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Jefferies upgrades Instil Bio to "Buy" with a $52 target, anticipating significant growth for PD-(L)1xVEGF class and ...